RLF-100

Study at a Glance

Estimated Time Commitment

To be discussed

Eligibility

Hospitalized with COVID, need oxygen (ordinal 5)

Diagnosis Required

Hospitalized with COVID

Diseases Being Studied

SARS-CoV-2
Location: San Antonio, TX

Sponsor: NeuroRX

Coordinating Center/CRO: was Covance, effective 10/1 is now Prevail InfoWorks

Primary Objective: The primary objective of this study is to test the cohort-specific hypothesis that RLF-100 + best available Standard of Care (SOC) increases the proportion alive without progression to respiratory failure through Day 14.

Study drugs: Aviptadil vs placebo nebulized 3 times a day up to 14 days

Study progress: Enrollment currently on hold at study level.

Current enrollment: 1; First patient first visit July 9

Meet Your Clinical Research Team

Contact us

Principal Investigator: All Infectious Diseases Faculty

For questions on this study, please contact Dr. Barbara Taylor